Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias
- PMID: 15901610
- DOI: 10.1164/rccm.200502-210OC
Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias
Abstract
Rationale: Recent cohort studies in chronic obstructive pulmonary disease (COPD) have questioned the validity of previously reported associations between inhaled corticosteroids (ICS) and reductions in mortality and rehospitalization in observational studies. Using time-dependent versions of statistical survival models, these studies have suggested immortal time bias as responsible for the proposed beneficial association.
Objectives: We explored the extent of this bias in a study of patients with COPD monitored for a year from COPD discharge with two designs free of any immortal time bias in the General Practice Research Database in the United Kingdom.
Methods: In Design 1, we used only patients whose treatment status was defined on the same day of discharge to obtain a matched cohort based on propensity scores, which were derived from the patient-level baseline characteristics. In Design 2, we identified all in the study cohort who experienced death or rehospitalization and then matched each case to up to four noncases by randomly sampling from the cohort risk sets without regard to treatment status.
Measurements and main results: The propensity scores matched cohort analysis of 786 patients without a wait time found a significant risk reduction associated with use of ICS: hazard ratio, 0.69 (95% confidence interval, 0.52-0.93). The matched nested case-control analysis of 2,222 patients, designed without regard to exposure status and hence free of immortal time bias, gave a similar association with exposure to ICS in the last 6-month period: hazard ratio, 0.71 (0.56-0.90).
Conclusions: We conclude that immortal time bias cannot account for the risk reduction associated with ICS exposure in observational studies.
Comment in
-
Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias.Am J Respir Crit Care Med. 2006 Feb 15;173(4):464; author reply 464-5. doi: 10.1164/ajrccm.173.4.464. Am J Respir Crit Care Med. 2006. PMID: 16467177 No abstract available.
Similar articles
-
Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies.Am J Respir Crit Care Med. 2003 Jul 1;168(1):49-53. doi: 10.1164/rccm.200210-1231OC. Epub 2003 Mar 27. Am J Respir Crit Care Med. 2003. PMID: 12663327
-
Immeasurable time bias in observational studies of drug effects on mortality.Am J Epidemiol. 2008 Aug 1;168(3):329-35. doi: 10.1093/aje/kwn135. Epub 2008 May 30. Am J Epidemiol. 2008. PMID: 18515793
-
Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis.Am J Respir Crit Care Med. 2003 Dec 15;168(12):1488-94. doi: 10.1164/rccm.200301-019OC. Epub 2003 Oct 2. Am J Respir Crit Care Med. 2003. PMID: 14525798
-
Immortal time bias in pharmaco-epidemiology.Am J Epidemiol. 2008 Feb 15;167(4):492-9. doi: 10.1093/aje/kwm324. Epub 2007 Dec 3. Am J Epidemiol. 2008. PMID: 18056625 Review.
-
[Do inhaled corticosteroids reduce mortality in chronic obstructive pulmonary disease?].Rev Med Suisse. 2005 Nov 16;1(41):2673-4, 2677-9. Rev Med Suisse. 2005. PMID: 16355882 Review. French.
Cited by
-
Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.Am J Epidemiol. 2016 Aug 15;184(4):325-35. doi: 10.1093/aje/kwv445. Epub 2016 Jul 25. Am J Epidemiol. 2016. PMID: 27455963 Free PMC article.
-
Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.Proc Am Thorac Soc. 2008 May 1;5(4):506-12. doi: 10.1513/pats.200707-096ET. Proc Am Thorac Soc. 2008. PMID: 18453363 Free PMC article. Review.
-
Commentary: Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis.Front Med (Lausanne). 2022 Oct 31;9:1051526. doi: 10.3389/fmed.2022.1051526. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36388893 Free PMC article. No abstract available.
-
The benefits of combined treatment with corticosteroids and long-acting beta agonists.Int J Chron Obstruct Pulmon Dis. 2006;1(3):207-8. doi: 10.2147/copd.2006.1.3.207. Int J Chron Obstruct Pulmon Dis. 2006. PMID: 18046857 Free PMC article. No abstract available.
-
Metformin and Reduced Risk of Cancer in the Hong Kong Diabetes Registry: Real Effect or Immortal Time Bias?J Gen Intern Med. 2019 Jul;34(7):1154-1157. doi: 10.1007/s11606-019-04982-z. Epub 2019 Apr 25. J Gen Intern Med. 2019. PMID: 31025306 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical